Talzenna (talazoparib)

pCPA File Number: 23360

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

PC0417-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable